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Abstract In this study we investigated the possibility of treating 
Heymann's Nephritis (HN) by destroying antibody producing 
ceils by targetting a toxin, gelonin - conjugated to gp330, the 
renal brush border antigen. HN was induced in rats by immuniz- 
ing them with purified gp330. The gelonin-gp330 conjugate was 
administered 12 days after the antigenic challenge. Serum was 
screened for circulating antibodies. Proteinurea was estimated. 
The gp330-gelonin conjugate-treated animals had a circulating 
antibody titre in the serum much lower than that of diseased 
(untreated) animals. Proteinurea seen in diseased animals was not 
observed in treated animals. This work suggests the possibility of 
using a toxin-antigen conjugate for immunomodulating antibody 
mediated autoimmune renal disease. 
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1. Introduction 
Heymann's Nephritis is an autoimmune disease, that can be 
experimentally induced in rats. It has been used extensively as 
a model to study membranous glomerulonephropathy in hu- 
mans. This disease was first induced by Heymann in 1959 [1], 
by immunizing rats with kidney cortex homogenate in Freunds 
Complete Adjuvant. The disease is initiated by circulating anti- 
bodies [2,3], which deposit on the epithelial aspect of the glom- 
erular capillary wall resulting in heavy proteinuria [4]. It has 
been shown that the antigen is a glycoprotein [5] located in the 
membrane of the proximal tubule brush border of the rat kid- 
ney [6], sharing a high homology with the low density lipopro- 
tein receptor (LDLR) [7] and is called gp330. 
As circulating antibodies eem to be the mediators of HN, 
causing glomerular pathology and proteinuria, activation of 
specific B cells appears to be the pivotal event in the evolution 
and pathogenesis of this disease [8]. Hence, we felt that destruc- 
tion of B-cells expressing anti-gp330 on their surface could 
prevent he subsequent s eps in the pathway leading to severe 
kidney damage. Immunosuppressants have been used in the 
prevention of immune complex deposition in glomerulonephri- 
tis induced in rats [9]. As they are nonspecific and have a 
generalised action on lymphocytes, it would be more efficacious 
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to use specific drug targetting directed to gp330 primed cells. 
This can be achieved by directing a toxin, like gelonin, a plant 
ribosome inactivating protein [10] to these cells. The toxin was 
conjugated to gp330 with the help of a heterobifunctional 
crosslinking agent N-succinimidyl-3-(2-pyridyldithio) pr pion- 
ate (SPDP). In this report we show, using biochemical tech- 
niques, how a toxin conjugate is useful in ameliorating the 
damaging effects of this autoimmune disease of the kidney. 
2. Materials and methods 
2.1. Animals 
Two strains of rats were obtained from the Central Animal Facility 
(CAF), Indian Institute of Science, Bangalore. These were namely Wis- 
tar and IISc strains. The latter are inbred Wistar ats maintained atthe 
CAF and found by us to be more susceptible to autoimmune disease. 
The animals used were approximately allof the same age (16 18 weeks) 
and female, and were fed ad libitum with chow pellets and water during 
the entire course of the experiment. 
2.2. Preparation of gp330 
Crude cortex preparation: The antigen gp330 was prepared according 
to the combined methods of Malathi et al. [11] and Kerjaschki and 
Farquhar [7]. Sephacryl S-300 and Sepharose 4B were purchased from 
Pharmacia Biotech, Sweden. Lentil ectin was prepared according to the 
method of Hayman and Crumpton [12] and coupled to Sepharose 4B 
as described by March et al. [13]. The sample was tested for purity by 
SDS-PAGE as described by Kerjaschki and Farquhar [7]. 
2.3. Preparation of Gelonin 
Gelonium multiforum seeds were purchased from United Chemical 
and Allied products, Calcutta. Gelonin was extracted from these seeds 
as described by Stirpe et al. [14]. Its purity and activity were tested by 
SDS-PAGE and the extent o which it inhibited protein synthesis in a 
rabbit reticulocyte lysate. 
2.4. Preparation of gelonin-gp330 conjugate 
The gelonin-gp330 conjugate was prepared based on the method of 
Pain and Surolia [15] using the heterobifunctional crosslinking agent 
SPDP. The purity and efficacy of the product was tested for by SDS- 
PAGE and inhibition of the protein synthesis as for gelonin. 
2.5. Preparation of anti-gelonin-Sepharose aJfinity column 
Antibodies against gelonin were raised in rabbits. The IgG fraction 
was purified using Protein G-Sepharose. The purified IgG was coupled 
to Sepharose 4B according to the method of March et al. [13]. 
2.6. In vitro inhibition of protein synthesis" 
Rabbit reticulocyte lysate was prepared as described by Jagus [16]. 
The efficiency of the lysate was tested using [35S]methionine i  the 
cocktail, which also contained DTT. The ability of gelonin and gelonin 
gp330 to inhibit protein translation was then carried out using this 
system. 
2. 7. Induction of active HN 
Adult IISc strain rats were administered two foot pad injections with 
100 ~tg purified gp330 in Freunds Complete Adjuvant in a total volume 
of 400 pl on day 0 and day 8. Simultaneously a control antigen, namely 
40 pg of ovalbumin (Sigma) was injected. 
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2.8. Administration of gelonin gp330 conjugate, or gp330 or gelonin 
The animals in which active HN had been induced were divided into 
five groups. Each group consisted of eight rats. The first group (G-I) 
was given a placebo namely phosphate-buffered saline (PBS). The sec- 
ond group (G-II) was given gelonin (40 #g) and the third group (G-Ill) 
was administered gp330 (450#g) in a similar schedule as for the gelonin- 
gp330 conjugate. The fourth group was further subdivided into 
2 groups (G-IV and G-V, respectively) and intravenously injected with 
two different doses of the conjugate, one set was given 250 #g while the 
other was given 500 #g. The conjugate, gelonin and gp330 were dis- 
solved in 0.9% NaCI containing 0.018 mg of invertase per 100 g body 
weight of the rat and administered on the 4th day after the second 
immunization. 
2.9. Detection of anti-gp330 antibodies inserum 
Blood samples were taken from all animals at bi-weekly intervals 
starting from the 2nd week after initiating the experiment (day 0). The 
circulating anti-gp330 antibodies present in the serum were detected 
using the dot-blot assay. The circulating antibody titre was determined 
as described by Matsukawa et al. [17]. Briefly, serum samples were 
serially diluted in 0.02 M PBS pH 7.2, according to the general formula 
1:4  TM X 1000 where N varied from 04. The titre was determined as the 
highest dilution of the serum giving positive dot blot assay. Antibodies 
against ovalbumin were also tested for in the same manner as for 
anti-gp330 antibodies. 
2.10 In vitro production of anti-gp330 antibodies by lymph node cells" 
The production of anti-gp330 antibodies by brachial and axillary 
lymph node cells taken from the front legs was assessed as described 
by De Heer et al. [8]. 
2.11 Urine analysis 
Rats were kept in metabolic ages for 24 h and urine samples were 
collected. This was done every alternate week to the week blood was 
collected. The quantity of protein in the urine was estimated by Lowry's 
method [18], after dialysing out urea, and other small molecular weight 
components. Proteinuria was graded according to the amount excreted. 
3. Results 
3.1. Efficiency of gelonin and gelonin-gp330 conjugate 
Gelonin is a single chain ribosome inactivating protein. It 
was conjugated to gp330 using SPDP. Free gelonin was sepa- 
rated from gelonin-gp330 by gel filtration through a Sephadex 
G-100 column. More than 90% of the conjugate was retained 
on an anti-gelonin-Sepharose affinity matrix, indicating the 
absence of any free gp330. To assess the stoichiometry of 
gp330: gelonin in the conjugate it was rechromatographed, on 
the same gel filtration column, in the presence and absence of 
DTT (Fig. 1). Under reducing conditions two protein peaks 
comprising of gp330 and gelonin were obtained. Based on the 
protein content of each peak, the molar ratio of gp330 and 
gelonin calculated to be 1 : 1. 
The efficacy of gelonin and gelonin-gp330 conjugate were 
tested in vitro using rabbit reticulocyte lysate, containing DTT 
Table 1 
In vitro production of anti-gp330 antibodies by lymph node cells of 
treated and untreated rats. N is normal animal. G-I to G-V are groups 
I to V as mentioned in materials and methods 
No. of Antibody produced in ng 
cells/well 
N G-I  G-I1 G-Ill G-IV G-V 
1 × 10 7 2.1 8.2 7.9 7.6 3.6 2.8 
2.5 X 10 7 3.2 18 25 22 5.7 3.7 
5.0 X l0  7 2.7 43 40 35.8 7.2 5.2 
10.0X 10 7 3.6 96 92 98 9.1 6.8 
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Fig. 1. Gel filtration of gelonin-gp330 conjugate on a Sephadex G-100 
column in the presence (e) and absence of DTT (o). Under reducing 
conditions two peaks are obtained, one which appears in the void 
volume and corresponds togp330 while the other is in the inner volume 
and elutes at the same position as gelonin. 
in the cocktail mixture. The concentration of gelonin required 
to achieve 50% inhibition was 13.8 ng/ml and for 80% inhibition 
was 35 ng/ml (1.13 nM) which is similar to that reported by 
Stirpe et al. [14]. The conjugate also inhibited 80% protein 
synthesis at a similar concentration (l.01 nM) (Fig. 2). Thus, 
these results reinforce the point that (a) conjugation of gelonin 
by SPDP did not destroy its activity in vitro, in fact we also 
found that if the molar ratio of gelonin: SPDP is kept to 1 in 
the reaction mixture the activity of the toxin is not compro- 
mised at all; (b) gelonin is conjugated to gp330 with a stoi- 
chiometry of 1 : 1. 
3.2. Detection of anti-gp330 antibodies in serum 
The experimental nimals in which HN had been induced can 
be essentially classified into two groups: (a) untreated animals, 
rats which received PBS, or gelonin or gp330 only as controls; 
(b) treated animals, rats which were intravenously administered 
with the gelonin-gp330 conjugate. 
Within two weeks of sensitising the rats with gp330, the 
animals were found to have circulating antibody in the serum, 
reaching a maximum titre by the 21st day. Subsequently, the 
antibody titre tempered gradually, to relatively undetectable 
levels by 168 days (Fig. 3). Further, administration of gelonin 
alone or a third dose of gp330 on 12th day (Group II and 
Group III respectively, Fig. 3) did not alter the serum antibody 
levels and remained same as in Group I, with disease. On the 
other hand intravenous administration of gp330-gelonin conju- 
gate has resulted in significant fall in circulating antibody titres, 
more so in Group V, which received a higher concentration 
(500 #g) of the conjugate. This indicates that booster with 
gp330 or the administration of gelonin alone does not amelio- 
rate the condition, nor the antibody response. With time in 
groups I, II and III, the antibody levels in the serum declined, 
but by then Heymann's Nephritis was well established as evi- 
denced by proteinuria. 
3.3. Production of anti-gp330 antibodies by lymph nodes 
To test our hypothesis that gp330-gelonin was indeed killing 
antibody producing cells we assessed the in vitro production of 
antibodies by cells in the lymph nodes. 
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Fig. 2. In vitro inhibition of protein synthesis by gelonin (o) and ge- 
lonin-gp330 conjugate (o). IC50 of gelonin and gelonin-gp330 are 
0.45 nM and 0.40 nM, respectively. 
We observed that antibody production by lymph node cells 
from treated animals was negligible as compared with cells 
isolated from animals which had not received any conjugate. 
As in the case of circulating antibodies, the titre was high for 
groups I, II and III while it was just above threshold level for 
groups IV and V (Table 1). When an unrelated control antigen, 
ovalbumin, was coated in the wells instead of gp330 there was 
no production of antibody against ovalbumin by the lymph 
node cells isolated from the diseased animals (results not 
shown). 
3.4. Urine analysis 
Urine samples collected from the two classes of rats, treated 
and untreated, were graded according to the degree of protein- 
uria. 
In our preliminary experiments, we had collected urine from 
the second week after induction of HN, and found that protein- 
uria was manifested only after the 8th week. Hence, urine was 
collected for a period of 20 h every 14 days from the 56th day 
to the 168th day. Urinary protein content in untreated animals 
initially (at 56th day) was approximately 1 mg/20 h, with time 
there was a steady increase in the protein excreted, till it reached 
about 190 rag/20 h, and remained at this point even at the 126th 
day then, at the 140th day it was found to have diminished to 
about 160 rag/20 h and remained at this level till animals were 
sacrificed after the 168th day (Fig. 4). 
The conjugate treated rats (Group IV and V) had negligible 
levels of proteinuria during the course of the study, similar to 
control rats (Fig. 4). 
4. Discussion 
Toxins conjugated to proteins have been used widely in selec- 
tively killing target cells [19]. Most plant toxins act by inhibiting 
protein synthesis machinery. The most commonly used plant 
toxin is probably ricin. However, due to the presence of its B 
chain, it could bind to non-target cells as well. Removal of the 
B-chain seems to lower toxicity of the molecule by a thousand 
fold [20]. This is overcome by using single chain polypeptide 
toxins like gelonin, which is known to be non toxic to intact 
cells [10]. 
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Immunotoxins have been used in immuno and cancer ther- 
apy, and in some cases clinical trials have also begun (reviewed 
in [19,21,22]). The in vitro and ex vivo use of toxin-antigen 
conjugates for the therapy of myasthenia gravis, where serum 
antibodies are formed against he acetylcholine r ceptor, have 
also been reported [23,24]. In the present study, we have shown 
that the administration of gp330-gelonin conjugate into rats 
with Heymann's Nephritis, could alter the course of the disease, 
offering a protective ffect. This is probably brought about by 
selective killing of the specific gp330 antibody producing cells 
in the circulation, as seen by the reduction in antibody produc- 
tion by cells of the lymph node in vitro. This leads to a reduc- 
tion in circulating antibody levels, reducing the load on the 
glomerular filtration of these immunoglobulins and indirectly 
abrogating proteinuria. 
The fact that gp330-gelonin conjugate is antigen specific is 
indicated by the unaltered immune response against an unre- 
lated control antigen, ovalbumin. The in vivo efficacy of the 
conjugate in alleviating the clinical and pathological symptoms 
of HN has been documented by a variety of biochemical mark- 
ers, which include marked reduction in circulating antibodies 
as compared to untreated animals and the absence of protein- 
uria. Equivalent amounts of either gelonin (40/lg) or gp330 
(450/lg) alone displayed no therapeutic efficacy in abrogating 
HN. This excludes any non-specific immunosuppressive effect 
of either gelonin or gp330 moiety on HN. 
The results reported here establish two points: (a) the toxin- 
protein conjugates are effective as therapeutic agents in autoim- 
mune diseases, where the cells, implicated in the disease (in this 
case B cells), can be selectively destroyed; (b) membranous 
glomerulonephritis is initiated by circulating antibodies, as pro- 
teinuria can be prevented by the destruction of B cells produc- 
ing antibodies against gp330, thereby corroborating the evi- 
dence of Van Damme t al. and Couser et al. [2,3]. Most immu- 
notoxins are composed of antibody or anti-idiotypic antibody 
linked to a toxin molecule. This approach is valuable when 
dealing with autoimmune diseases caused by an antigen with 
a single epitope or those antigens which display an antigenic 
region confined to a single site, as is observed for the main 
immunogenic region in acetylcholine receptor [25]. However, 
for antigens uch as gp330, which evokes antibodies against 
multiple epitopes [26], it would be practical to use the whole 
300 
N 
250 ~i  G-I 
o ~ C-Ill 
-- 200 E2Z} C,-IV >:  
~, [Eli O-V 
= 150 
0 
= 100 
14 21 55 49 65 77 
Ooys 
Fig. 3. Circulating anti-gp330 antibodies. The N value titre (as ex- 
plained in materials and methods) isplotted against the day serum was 
collected from the orbital vein of the rat. 
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Fig. 4. Sequential urinary protein secretion in the different groups of 
animals (LV). The values are a mean of the 8 rats in each group. 
molecule rather than any particular anti-idiotypic antibody. 
This would ensure the destruction of B-cells producing antibod- 
ies directed against all the epitopes of the antigen. 
The fact that the conjugate has been effective in significantly 
diminishing the amount of circulating antibodies and prevent- 
ing proteinuria, shows that it can be considered as a therapeutic 
modality in autoimmune nephritis. 
|mmunonosuppressants like FK506 [20] and cyclosporin A
[13], also have been used in the therapy of immunemediated 
diseases. However, their nonspecific and generalised action on 
the immune system, usually necessitates antibiotic therapy to 
ward of infections as occurring as a secondary phenomenon. 
Hence, our approach seems to be more specifically targeted to 
cells implicated in the disease, and could have a wider applica- 
tion in autoimmune therapy. 
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